Sarilumab

Approval in adults and children aged 6 years and older supported by Phase 3 trial demonstrating Dupixent significantly reduced nasal signs and symptoms, and systemic corticosteroid use or surgery compared to placebo AFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring surgery with high rates of post-operative recurrence Dupixent is now approved in the U.S. to treat nine distinct diseases driven in part by type 2 inflammation, including sino-nasal, skin, gut and respiratory system diseases that affect a broad range of patients, from infants to elderly adults Feb. 24, 2026 -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adult and pediatric patients aged 6 years and older with allergic fungal rhinosinusitis (AFRS) who have a history of sino-nasal surgery. The FDA evaluated Dupixent under Priority Review for the treatment of AFRS, which is reserved for medicines that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. This approval expands our approved indications in sino-nasal diseases to now include AFRS, alongside chronic rhinosinusitis with nasal polyps. “Allergic fungal rhinosinusitis (AFRS) is a disease that can leave both children and adults with inflamed nasal passages, nasal polyps and thick mucus causing constant nasal congestion. Some patients can also experience more serious complications like deterioration of bone around the sinuses and facial deformities,” said Kenneth Mendez, President and CEO, Asthma and Allergy Foundation of America (AAFA). “As the first treatment specifically approved for AFRS, Dupixent offers the potential for relief to adults and children six years and older struggling with potentially debilitating symptoms.” AFRS is a chronic type 2 inflammatory disease. It is a specific subtype of chronic rhinosinusitis distinctly caused by an intense allergic hypersensitivity to fungi. It primarily affects people living in warm, humid climates where fungal spores are common in the environment. It can lead to nasal polyps, nasal congestion, loss of smell, thick mucus discharge, poor health-related quality of life, and patients can also experience bone loss around the sinus cavities and facial deformities. AFRS can be a severe and hard-to-treat form of chronic rhinosinusitis because it may not respond well to available options. Current standard-of-care treatment is surgery and prolonged courses of systemic steroids; however, disease recurrence is not uncommon. “With this approval, Dupixent once again demonstrates its value in advancing the treatment landscape for a chronic type 2 inflammatory disease with high unmet need,” said George D. Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “Beyond reducing nasal signs and symptoms, Dupixent reduced the need for surgery or systemic corticosteroids with fewer patients having bone erosion in the sinuses. These results underscore its potential to establish a new standard of care for people living with AFRS. This ninth FDA approval for Dupixent, the most widely used innovative branded antibody medicine, strengthens the established efficacy and body of evidence that IL-4 and IL-13 are major drivers of type 2 inflammation across many chronic diseases.” The FDA approval is supported by the LIBERTY-AFRS-AIMS Phase 3 trial, in which 62 adults and children aged 6 years and older with AFRS were randomized to receive an age- and weight-based dose of Dupixent (200 mg or 300 mg) every two or four weeks (n=33) or placebo (n=29). The differences for Dupixent compared to placebo were as follows: Primary Endpoint: Sinus opacification scores (a measure of extent of sinus involvement by the disease as assessed by computed tomography [CT] scans) improved by 50% versus 10% at Week 52 (7.36-point placebo-corrected reduction; p<0.0001); a significant reduction in sinus opacification scores was also observed at Week 24 (p<0.0001). Secondary Endpoints: Select nasal signs and symptoms Patient-reported nasal congestion/obstruction improved by 67% versus 25% at Week 24 (0.87-point placebo-corrected reduction; p<0.0001), with continued improvement at Week 52 to 81% compared to 11% (1.40-point placebo-corrected reduction; p<0.0001). Nasal polyp size (as assessed by endoscopy) reduced by 61% versus 15% at Week 24 (2.36-point placebo-corrected reduction; p<0.0001), with continued reduction of 63% compared to 4% up to Week 52 (2.77-point placebo-corrected reduction; p<0.0001). Sense of smell Patient-reported loss of smell reduced by 67% versus 19% at Week 24 (0.89-point placebo-corrected reduction; p<0.0001). Treatment burden 92% reduction in the risk of systemic corticosteroid use and/or need of surgery (29% fewer proportion of patients; p=0.0010) over 52 weeks. 3% or 0% of patients on Dupixent received systemic corticosteroids or had surgery, respectively, compared to 31% or 7% of patients on placebo. The safety results in the LIBERTY-AFRS-AIMS trial were similar to the known safety pro Dupixent in CRSwNP. In pooled data from two pivotal CRSwNP trials in adults, the most common adverse reactions (≥1%) in the U.S. Prescribing Information more frequently observed in patients on Dupixent compared to placebo were injection site reactions, conjunctivitis, arthralgia, gastritis, insomnia, eosinophilia, and toothache. “Before Dupixent, people living with allergic fungal rhinosinusitis had to rely on treatments that left them potentially vulnerable to regrowth of nasal polyps and thick mucus that could rob them of their sense of smell,” said Alyssa Johnsen, M.D., Ph.D., Global Therapeutic Area Head, Immunology Development at Sanofi. “As the first medicine approved specifically for AFRS, Dupixent has been proven to lessen multiple signs and symptoms of disease, help break the cycle of recurrence, and reduce the risk for subsequent surgeries and corticosteroids by 92%. We look forward to working with regulators in other countries to bring this innovative option to more patients in need.” Additional submissions are planned to other regulatory authorities around the world. The LIBERTY-AFRS-AIMS Phase 3 trial was a randomized, double-blind, placebo-controlled trial assessing the safety and efficacy of Dupixent in adults and children aged 6 years and older with AFRS. The 52-week trial included an age- and weight-based dose of Dupixent (300 mg every two weeks for adults and children weighing ≥60 kg, 200 mg every two weeks for children weighing ≥30 kg to <60 kg or 300 mg every four weeks for children weighing ≥15 kg to <30 kg) or placebo. More than 80% of patients had a history of type 2 comorbidities. The primary endpoint assessed change from baseline in sinus opacification assessed by CT scans using the Lund-Mackay score (LMK; scale: 0-24) at Week 52. Secondary endpoints assessed at Week 24 included: Change from baseline in patient-reported nasal congestion (NC; scale: 0-3). Change from baseline in nasal polyp score (NPS; scale: 0-8) as measured by endoscopy. LMK score. Change from baseline in patient-reported loss of smell (LoS; scale: 0-3). Some secondary endpoints were also assessed at Week 52 in addition to proportion of patients requiring surgery or systemic corticosteroids during the treatment period. Proportion of patients with bone erosion in the sinuses as evaluated by CT scans was a tertiary endpoint assessed at Week 52. Dupixent is an injection administered under the skin (subcutaneous injection) at different injection sites. In adults with AFRS, Dupixent 300 mg is administered every two weeks. In children with AFRS, Dupixent is administered based on weight: 300 mg every two weeks for ≥60 kg, 200 mg every two weeks for ≥30 kg to <60 kg or 300 mg every four weeks for ≥15 kg to <30 kg. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home after training by a healthcare professional. In children aged 12 to 17 years, Dupixent should be administered under the supervision of an adult. In children younger than 12 years of age, Dupixent should be administered by a caregiver if given at home. Dupixent, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways and is not an immunosuppressant. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase 3 trials, establishing that IL-4 and IL-13 are two of the key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases. Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay program. Dupixent has received regulatory approvals in more than 60 countries in one or more indications including certain patients with atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), prurigo nodularis, chronic spontaneous urticaria (CSU), chronic obstructive pulmonary disease (COPD), bullous pemphigoid (BP) and allergic fungal rhinosinusitis (AFRS) in different age populations. More than 1,400,000 patients are being treated with Dupixent globally.1 Regeneron's VelocImmune technology utilizes a proprietary genetically engineered mouse platform endowed with a genetically humanized immune system to produce optimized fully human antibodies. When Regeneron's co-Founder, Board co-Chair, President and Chief Scientific Officer George D. Yancopoulos was a graduate student with his mentor Frederick W. Alt in 1985, they were the first to envision making such a genetically humanized mouse, and Regeneron has spent decades inventing and developing VelocImmune and related VelociSuite ® technologies. Dr. Yancopoulos and his team have used VelocImmune technology to create a substantial proportion of all original, FDA-approved fully human monoclonal antibodies. This includes Dupixent ® (dupilumab), Libtayo ® (cemiplimab-rwlc), Praluent ® (alirocumab), Kevzara ® (sarilumab), Evkeeza ® (evinacumab-dgnb), Inmazeb ®(atoltivimab, maftivimab and odesivimab-ebgn) and Veopoz ® (pozelimab-bbfg). In addition, REGEN-COV ® (casirivimab and imdevimab) had been authorized by the FDA during the COVID-19 pandemic until 2024. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 12,000 patients with various chronic diseases driven in part by type 2 inflammation. In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes in Phase 3 trials, including chronic pruritus of unknown origin and lichen simplex chronicus. These potential uses of dupilumab are currently under clinical investigation, and the safety and efficacy in these conditions have not been fully evaluated by any regulatory authority. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontier of medicine with data-powered insights from the Regeneron Genetics Center ® and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases. Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. The content above comes from the network. if any infringement, please contact us to modify.

点击关注小白学药 一周行业速览: FDA 终结双试验审批; ADC 峰会启幕; 礼来1亿美元押注IL-6单抗 2026 年 2 月下旬，全球生物医药领域迎来多重重磅动态：FDA 官宣简化新药审批标准，终结 “双试验” 传统；欧洲 ADC 行业峰会即将召开；Lilly 1 亿美元布局抗炎管线，行业创新与监管变革同步加速。一、FDA 重磅政策：单关键试验成新药审批 “默认标准” 近日，FDA Commissioner Marty Makary 与FDA官员 Vinay Prasad 在《新英格兰医学杂志》宣布，将正式终结始于 1960 年代的 “双关键试验” 审批要求，未来新药获批的 “默认标准” 将改为一项高质量关键试验 + 验证性证据，这一政策变革旨在降低研发成本、加速药物可及性，且不降低监管标准。政策核心亮点：变革逻辑 FDA 认为，现代生物技术、统计科学与试验设计的进步，已能通过生物机制验证、生物标志物数据等多重维度保障药物可信度，无需依赖两项重复试验避免统计偶然。 数据显示，2020 年超半数新上市药物已通过单试验获批，近五年 60% 首创药物依赖单试验 clearance。适用范围 将主要惠及眼科、精神病学、免疫学、心血管等领域药物，癌症与罕见病药物此前已享受单试验审批灵活性，本次政策将覆盖更多常见疾病。安全保障 FDA 强调将强化上市后数据收集，并保留特殊情况下要求双试验的权力；审批焦点将转向试验质量，包括对照组合理性、终点选择、统计效力等核心指标。行业影响 Jefferies 分析师 Andrew Tsai 指出，政策将降低药企研发成本，缓解药价高企的核心争议，但可能增加部分开发者的单次试验风险，已启动双试验的企业需重新评估路径。 值得关注的是，该政策发布前，FDA 刚因试验数据不足拒绝 Moderna 新型流感疫苗申请，后又反转决定，显示其在不同品类药物监管上的差异化态度，行业期待政策落地后的统一执行标准。二、16 届世界 ADC 伦敦峰会启幕，聚焦下一代技术突破 2 月 23 日 - 26 日，欧洲规模最大的 ADC 专业论坛 —— 第 16 届世界 ADC 伦敦峰会将在 London 举办，吸引全球近千位生物药企决策者、肿瘤学 KOL、投资者及监管机构代表参与。 本次峰会以 “突破耐药壁垒，推动 ADC 向一线治疗进阶” 为核心，设置 5 大内容板块，超百位全球专家将围绕下一代载荷技术、双特异性 ADC 构建、双载荷策略、非抗体偶联物等前沿方向展开深度讨论，同时涵盖临床开发、规模化生产与监管策略等实操议题。 峰会还设置 14 小时专项 networking 环节，为全球 ADC 领域合作、授权与投资提供高效对接平台，有望催生更多技术转化与商业合作。三、Lilly 1 亿美元布局 IL-6 单抗，加码抗炎赛道 2 月 18 日，礼来（Eli Lilly）宣布与澳大利亚生物药企 CSL 达成协议，以 1 亿美元预付款获得 IL-6 靶向单抗 clazakizumab 的多适应症开发权益，CSL 将保留终末期肾病相关心血管并发症适应症（目前处于 III 期试验阶段），并有权获得后续里程碑付款与销售分成。交易背后： clazakizumab 通过抑制 IL-6 细胞因子过量产生发挥抗炎作用，此前由 Vitaeris 研发，2020 年随公司被 CSL 收购，曾开展肾移植排斥预防试验但因疗效不足提前终止。 Lilly 凭借肥胖与糖尿病药物的现金流优势，近年频繁通过并购补强管线，此次布局 IL-6 靶点，将与旗下 IL-13 抑制剂 Ebglyss 形成抗炎管线协同，挑战 Roche Actemra、Sanofi/Regeneron Kevzara 等现有 IL-6 领域重磅药物。行业趋势： 监管简化、技术迭代与商业并购成为 2026 年生物医药行业关键词。 FDA 审批政策的松动将加速创新成果转化，而 ADC、抗炎等热门赛道的技术突破与资本聚焦，有望推动行业进入 “高效创新 + 精准布局” 的新阶段。 #礼来 #生物医药 #FDA政策 #ADC大会 #医药动态 点击关注小白学药 喜欢就点个感恩一路相伴 推荐阅读小白学药祝大家：马年大吉！财源滚滚！国产ADC的2026, 凭什么成爆发元年? 恒瑞十连破、新诺威拓靶点、华东拿下 FDA 孤儿药, 国产创新改写全球肿瘤治疗格局！ADC爆发元年, 赢在CDMO联盟: 端到端加速研发, 降本又提速！致敬科技她力量! 2026全球生物技术领域7位影响力女性, 正在改写医药未来ADC | 双喜临门! 刘勇军携2.8亿融资创业, 周伟昌当选美国工程院院士全球ADC新浪潮来袭! 8 家Biotech领跑下一代创新, 2034 年市场将破 600亿美元创新药(五) | 千亿出海、首次盈利、30天审批：2025，中国创新药终于站上世界C位创新药(四) | 不止ADC! 核药、AI制药、New Co模式崛起, 从卖产品到定规则, 中国创新药 License-out 全球第二!创新药(三) |  ADC出海, 双抗破冰, CGT普惠: 中国创新药商业化“最后一公里”打通了！2026 年全球生物制药领域核心会议指南：见证医学突破与行业风向医药人必藏双平台:「小白学药」公众号+视频号艾伯维双抗命悬一线, 但故事没完! ADC赛道再添狠角色! 乐天生物, 2026 新基地剑指全球GSK联手韩国公司, 改写PD-1给药规则; 2026 Biotech复苏藏三大隐忧！下一代抗体药物浪潮来袭：ADC、双抗领衔，研发、生产、商业化全解析艾伯维ADC落地韩国改写卵巢癌治疗; 弼领生物 2 亿 B 轮加码纳米偶联破解耐药+全球突围! 信达三抗获FDA快车道, 亚洲43%创新管线领跑世界 声明：本公众号所有推文不构成任何投资意见和建议，其中科普性质内容，非医疗建议。转载请注明出处：小白学药公众号。部分内容源于网络公开信息，仅用于交流学习传播知识，侵删。因水平有限，若出现错误，欢迎指出。